• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Faron Pharmaceuticals Ltd - Articles and news items

First patient recruited for Phase III Japanese acute respiratory distress syndrome trial

Industry news / 27 October 2016 / Niamh Louise Marriott, Digital Content Producer

The Japanese Phase III clinical trial is a double-blinded, randomised, parallel-group comparison of efficacy and safety of FP-1201-lyo against placebo…

Positive top-line results from the Japanese Phase II study of Traumakine® for the treatment of ARDS

Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS

Industry news / 7 January 2016 / Nicholas Jackson

Faron has announced that its Japanese licensing partner Maruishi has obtained positive results from the Phase II Japanese study for Traumakine conducted by Maruishi in Japan…

Faron announces intention to float on AIM

Industry news / 7 September 2015 / Victoria White

Faron’s admission to AIM will support development of its lead candidate, Traumakine, into a Phase III Study and the development of its preclinical cancer immunotherapy candidate, Clevegen…

Faron and CMS enter into strategic agreement for the development of Traumakine in China, Hong Kong, Macao and Taiwan

Industry news / 26 May 2015 / Victoria White

Faron has entered into strategic agreements with CMS and A&B Ltd for the development and commercialisation of Traumakine for the treatment of ARDS…


Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +